STOCK TITAN

Fortrea (FTRE) Director Reports 62,500-Share Purchase at ~$6.5 Average

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Fortrea Holdings director Peter M. Neupert reported two open-market purchases of the issuer's common stock: 30,000 shares on 08/08/2025 at a weighted average price of $6.79, and 32,500 shares on 08/11/2025 at a weighted average price of $6.26. The filing notes the trades were executed in multiple fills at price ranges of $6.69–$6.90 and $6.15–$6.39, respectively.

After these transactions the reporting person beneficially owned 98,132 shares. The Form 4 was signed by an attorney-in-fact on 08/11/2025. No derivative transactions or dispositions were reported on this form.

Positive

  • Director Peter M. Neupert purchased a total of 62,500 shares in two open-market transactions
  • Beneficial ownership increased to 98,132 shares following the reported purchases
  • Transactions reported with weighted average prices and execution price ranges, aiding transparency

Negative

  • None.

Insights

TL;DR Insider purchases totaling 62,500 shares raise the director's stake to 98,132 shares, a potentially positive signal to the market.

Two separate open-market purchases on 08/08/2025 and 08/11/2025 increased the reporting person's direct holdings from the prior reported level to 98,132 shares. The transactions executed at weighted average prices of $6.79 and $6.26 show increased insider accumulation over a short window. From a trading perspective, the size and timing are notable for investors tracking insider activity, though the filing does not disclose intent or percentage ownership relative to outstanding shares.

TL;DR Routine Section 16 disclosure: open-market purchases reported and form signed by an attorney-in-fact; no derivative activity or sales disclosed.

The Form 4 documents compliance with Section 16 reporting for a director-level reporting person. Purchases were reported with weighted average prices and explanatory ranges, and the form bears a signature by an attorney-in-fact, indicating proper execution. There are no exercised options, grants, dispositions, or plan-designation boxes checked on this filing to suggest other governance events.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
NEUPERT PETER M

(Last) (First) (Middle)
8 MOORE DRIVE

(Street)
DURHAM NC 27709

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fortrea Holdings Inc. [ FTRE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 08/08/2025 P 30,000 A $6.79(2) 65,632(3) D
Common Stock(1) 08/11/2025 P 32,500 A $6.26(4) 98,132(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The purchases reported on this Form 4 represent shares of Common Stock purchased by the Reporting Person.
2. This transaction was executed in multiple trades at prices ranging from $6.69 to $6.90. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This number reflects the aggregate amount of Common Stock held by the reporting person.
4. This transaction was executed in multiple trades at prices ranging from $6.15 to $6.39. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
/s/ James Stillman Hanson, Attorney-in-Fact for Peter M. Neupert 08/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Peter M. Neupert report on Form 4 for FTRE?

The Form 4 reports purchases of 30,000 shares on 08/08/2025 at a weighted average price of $6.79 and 32,500 shares on 08/11/2025 at a weighted average price of $6.26.

How many FTRE shares does the reporting person beneficially own after the transactions?

Following the reported purchases the reporting person beneficially owned 98,132 shares.

Were any derivative securities or sales reported in this Form 4 for FTRE?

No. The filing contains only non-derivative purchase transactions and explicitly shows no derivatives or dispositions on this form.

Who signed the Form 4 for Peter M. Neupert and when was it signed?

The Form 4 was signed by James Stillman Hanson, Attorney-in-Fact for Peter M. Neupert on 08/11/2025.

What price ranges were disclosed for the trades on the Form 4?

The filing states the 08/08/2025 trades were executed at prices ranging $6.69–$6.90 and the 08/11/2025 trades at $6.15–$6.39.

What is the reporting person’s relationship to Fortrea Holdings (FTRE)?

The Form 4 identifies the reporting person, Peter M. Neupert, as a Director of Fortrea Holdings.
Fortrea Holdings

NASDAQ:FTRE

FTRE Rankings

FTRE Latest News

FTRE Latest SEC Filings

FTRE Stock Data

1.61B
91.87M
0.5%
111.46%
11.57%
Biotechnology
Services-medical Laboratories
Link
United States
DURHAM